AFINITOR® (everolimus) is indicated for the treatment of
- Hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor
- Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours (NET) of gastrointestinal or lung origin in adults with progressive disease; and for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease
- Patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy
Disclaimer: This is an international web site for AFINITOR® (everolimus) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located. If you are living outside the US and are not a healthcare professional, click here.
© 2018 Novartis AG